Use Case 2

Demonstrating innovative solutions for the removal of pharmaceutical contaminants

  • Location

Kalaat Al Andalouss, Tunisia

Use Case 2 - Tunisia
  • Leading partner

Opalia Pharma
  • Background

Pharmaceutical industry effluents typically receive limited treatment before being discharged into the environment or municipal sewage systems, primarily through the conventional Activated Sludge Process (ASP). Trace amounts of active pharmaceutical ingredients may enter the environment post-use, posing potential risks by contributing to drug-resistant bacteria and fungi.

  • Key facts

In a use case scenario, a remediation solution will be demonstrated at a pharmaceutical company in Kalaat Al Andalouss, Tunisia, to assess the removal efficiencies of pharmaceutical organic pollutants using both conventional ASP and an innovative microfluidic system, aiming to enhance treatment effectiveness.

  • Expected impacts

  • Achieve >95% degradation of emerging pharmaceutical contaminants from industrial effluents.
  • Contribute to over 50% reduction in pharmaceutical pollutants at their source compared to conventional techniques, meeting EU permissible limits.
  • Evaluate the performance of the monitoring box for efficient measurements of selected relevant chemicals in real wastewater treated directly at the source.